Drug intelligence / Profile preview

ITB100

Development stage: Preclinical
Lead developer: ITB-Med

Overview

ITB100 is a preclinical-stage therapeutic candidate being developed by ITB-Med, a biotechnology company focused on inducing immune tolerance. The asset is specifically intended for applications in organ transplantation, aiming to prevent graft rejection. As of 2024, ITB100 remains in the early research and development phase, and ITB-Med has not yet disclosed its specific molecular target or modality (e.g., monoclonal antibody, small molecule). It represents part of a broader pipeline of tolerance-inducing therapies, which includes the clinical-stage asset siplizumab.

Beyond the preview

Go deeper on ITB100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ITB100.